Abstract: Embodiments of methods and apparatuses for forming the metal oxide nanostructure on surfaces are disclosed. In certain embodiments, the nanostructures can be formed on a substrate made of a nickel titanium alloy, resulting in a nanostructure that can include both titanium oxide and nickel oxide. The nanostructure can be formed on the surface(s) of an implantable medical device, such as a stent.

Abstract: Embodiments of methods and apparatuses for forming the metal oxide nanostructure on surfaces are disclosed. In certain embodiments, the nanostructures can be formed on a substrate made of a nickel titanium alloy, resulting in a nanostructure that can include both titanium oxide and nickel oxide. The nanostructure can be formed on the surface(s) of an implantable medical device, such as a stent.

Abstract: Embodiments of nanostructures comprising metal oxide and methods for forming the nanostructure on surfaces are disclosed. In certain embodiments, the nanostructures can be formed on a substrate made of a nickel titanium alloy, resulting in a nanostructure containing both titanium oxide and nickel oxide. The nanostructure can include a lattice layer disposed on top of a nanotube layer. The distal surface of the lattice layer can have a titanium oxide to nickel oxide ratio of greater than 10:1, or about 17:1, resulting in a nanostructure that promotes human endothelial cell migration and proliferation at the interface between the lattice layer and human cells or tissue. The nanostructure may be formed on the outer surface of an implantable medical device, such a stent or an orthopedic implant (e.g. knee implant, bone screw, or bone staple).

Abstract: Embodiments of nanostructures comprising metal oxide and methods for forming the nanostructure on surfaces are disclosed. In certain embodiments, the nanostructures can be formed on a substrate made of a nickel titanium alloy, resulting in a nanostructure containing both titanium oxide and nickel oxide. The nanostructure can include a lattice layer disposed on top of a nanotube layer. The distal surface of the lattice layer can have a titanium oxide to nickel oxide ratio of greater than 10:1, or about 17:1, resulting in a nanostructure that promotes human endothelial cell migration and proliferation at the interface between the lattice layer and human cells or tissue. The nanostructure may be formed on the outer surface of an implantable medical device, such a stent or an orthopedic implant (e.g. knee implant, bone screw, or bone staple).

Abstract: Embodiments of nanostructures comprising metal oxide and methods for forming the nanostructure on surfaces are disclosed. In certain embodiments, the nanostructures can be formed on a substrate made of a nickel titanium alloy, resulting in a nanostructure containing both titanium oxide and nickel oxide. The nanostructure can include a lattice layer disposed on top of a nanotube layer. The distal surface of the lattice layer can have a titanium oxide to nickel oxide ratio of greater than 10:1, or about 17:1, resulting in a nanostructure that promotes human endothelial cell migration and proliferation at the interface between the lattice layer and human cells or tissue. The nanostructure may be formed on the outer surface of an implantable medical device, such a stent or an orthopedic implant (e.g. knee implant, bone screw, or bone staple).

Abstract: Embodiments of methods and apparatuses for forming the metal oxide nanostructure on surfaces are disclosed. In certain embodiments, the nanostructures can be formed on a substrate made of a nickel titanium alloy, resulting in a nanostructure that can include both titanium oxide and nickel oxide. The nanostructure can be formed on the surface(s) of an implantable medical device, such as a stent.

Abstract: Embodiments of nanostructures comprising metal oxide and methods for forming the nanostructure on surfaces are disclosed. In certain embodiments, the nanostructures can be formed on a substrate made of a nickel titanium alloy, resulting in a nanostructure containing both titanium oxide and nickel oxide. The nanostructure can include a lattice layer disposed on top of a nanotube layer. The distal surface of the lattice layer can have a titanium oxide to nickel oxide ratio of greater than 10:1, or about 17:1, resulting in a nanostructure that promotes human endothelial cell migration and proliferation at the interface between the lattice layer and human cells or tissue. The nanostructure may be formed on the outer surface of an implantable medical device, such a stent or an orthopedic implant (e.g. knee implant, bone screw, or bone staple).

Abstract: Disclosed are certain heterocyclic organic compounds that inhibit mitochondrial respiration and also lead to the maintenance of pluripotency of human embryonic stem cells in culture, even in the presence of oxygen. Exemplified are compounds, such as substituted 5-aminotetrazoles, which are reversible mitochondrial inhibitors. The pluripotency of the stem cells after culture is verified by the overexpression of pluripotent stem cell markers, exemplified by at least one of the genes NANOG, OCT4, and SURVIVIN after periods of culture in ambient oxygen.

Abstract: It has been discovered that inhibiting mitochondrial respiration in platelets reduces platelet activation or platelet aggregation. Certain heterocyclic compounds significantly reduced one or more platelet functions including clumping, sticking or platelet-stimulated clotting. Thus diseases or disorders mediated by inappropriately high levels of platelet activation or platelet aggregation can be treated by administering a therapeutically effective amount of a heterocyclic compound or nonheterocyclic mitochondrial inhibitor that significantly reduces one or more platelet functions including clumping, sticking or platelet-stimulated clotting, preferably in a reversible manner.

Abstract: Disclosed are certain heterocyclic organic compounds that inhibit mitochondrial respiration and also lead to the maintenance of pluripotency of human embryonic stem cells in culture, even in the presence of oxygen. Exemplified are compounds, such as substituted 5-aminotetrazoles, which are reversible mitochondrial inhibitors. The pluripotency of the stem cells after culture is verified by the overexpression of pluripotent stem cell markers, exemplified by at least one of the genes NANOG, OCT4, and SURVIVIN after periods of culture in ambient oxygen.

Abstract: It has been discovered that inhibiting mitochondrial respiration in platelets reduces platelet activation or platelet aggregation. Certain heterocyclic compounds significantly reduced one or more platelet functions including clumping, sticking or platelet-stimulated clotting. Thus diseases or disorders mediated by inappropriately high levels of platelet activation or platelet aggregation can be treated by administering a therapeutically effective amount of a heterocyclic compound or nonheterocyclic mitochondrial inhibitor that significantly reduces one or more platelet functions including clumping, sticking or platelet-stimulated clotting, preferably in a reversible manner.

Abstract: An illumination system enhances a manual human process associated with a multiwell plate having an array of wells thereon. The illumination system includes a compact self-contained apparatus including an illuminator coupled to a human interface. The human interface is configured to receive an operating parameter input and a start input. The illuminator has a protective surface for receiving the well plate and a plurality of underlying light sources configured to initiate a sequence of different well subarray indications in response to the start input and pursuant to the operating parameter input.

Abstract: Aqueous, fluorescent red ink jet inks which meet US Postal Service requirements for metered mail are disclosed and comprise an aqueous vehicle, a red or magenta pigment, a polymeric dispersant, a fluorescent dye and, optionally a hydrotrope additive.